Extended Data Fig. 8: LPCAT1 inhibits ferroptosis rely exogenous or endogenous SFA.
From: LPCAT1-mediated membrane phospholipid remodelling promotes ferroptosis evasion and tumour growth
a-b, left: Viability analysis of the indicated cells treated with RSL3 for 24 h. Right: IB analysis of LPCAT1 and LPCAT3 expression in the indicated cells. GAPDH served as a loading control. c-d, Viability analysis of the indicated cells, which were pretreated with the indicated concentration of TOFA for 24 h, followed by treatment with erastin or erastin plus ferrostatin-1 for 24 h, in the DFBS medium. e, Viability analysis of the indicated cells, which were pretreated with the indicated concentration of CAY10566 for 24 h, followed by treatment with erastin or erastin plus ferrostatin-1 for 24 h, in the DFBS medium. f, Viability analysis of the indicated cells, which were pretreated with the indicated concentration of palmitic acid and TOFA for 24 h, followed by erastin treatment for 24 h, in the DFBS medium. g, IB analysis of LPCAT1 expression in the indicated cells. h–k, Effects of ferroptosis inducer erastin on the growth of 3D tumour spheroids formed by the indicated cells treated with vehicle or with PA (50 mM) at the indicated time. Data are presented as mean ± SD, n = 3 biologically independent samples in a-k. Statistical analysis was performed using one-way ANOVA followed by Dunnett’s test in c-f, h-k, and two-way ANOVA followed by Tukey’s test in a-b. NS, not significant.
